Ciclopirox olamine
Based on 14 publication(s) in Google Scholar
Ciclopirox olamine (Ciclopirox ethanolamine) is a synthetic and orally active antifungal agent that can be used for superficial mycoses reseaech. Ciclopirox olamine has a very broad spectrum of activity and inhibits dermatophytes, yeasts, molds, and many Gram-positive and Gram-negative species pathogenic. Ciclopirox olamine also has anticancer and anti-inflammatory effect.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.78%
- No. CAS: 41621-49-2
- Fòrmula: C14H24N2O3
- Peso molecular:268.35
-
Almacenamiento:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-B0988
Deferoxamine mesylateIron Chelator -
HY-100579
Ferrostatin-1Ferroptosis Inhibitor -
HY-12726
Liproxstatin-1Ferroptosis Inhibitor -
HY-10219
RapamycinmTOR Inhibitor -
HY-17583
GriseofulvinAntifungal Antibiotic -
HY-N0135
Tanshinone IIAVEGFR Inhibitor -
HY-10162
OlaparibPARP Inhibitor -
HY-15531
VenetoclaxBCL-2 Inhibitor -
HY-114118
SemaglutideGLP-1R Agonist -
HY-A0004
DecitabineDNMT Inhibitor -
HY-17589A
ChloroquineAntimalarial Agent -
HY-N0303
IdebenoneMitochondrial Protectant/Antioxidant
Publications Citing Use of MedChemExpress (MCE) Ciclopirox olamine
More- Cell Death Dis. 2025 May 19;16(1):403. [Abstract]
- Cell Death Dis. 2024 Nov 1;15(11):786. [Abstract]
- Pharmacol Res. 2022 Feb:176:106046. [Abstract]
- Adv Healthc Mater. 2025 Mar;14(7):e2405085. [Abstract]
- Int J Mol Med. 2026 Oct;58(4):273.
- Clin Transl Med. 2022 Aug;12(8):e999. [Abstract]
- Redox Rep. 2026 Dec 31;31(1):2702136.
- J Agric Food Chem. 2025 Aug 13;73(32):20385-20395. [Abstract]
- Eur J Pharmacol. 2022 Sep 5:930:175156. [Abstract]
- Mol Neurobiol. 2025 Apr;62(4):4055-4075. [Abstract]
- mBio. 2026 Sep 9;17(9):e0116826.
- Front Pharmacol. 2021 May 10:12:670224. [Abstract]
- ACS Chem Biol. 2026 Jun 12. [Abstract]
- SSRN. 2025 Dec 4.
Customer Validation & Images
-
Flow Cytometry
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
WB
-
RT-PCR
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
>40 μM
Compound: CPX.Olamine
|
Inhibition of human ERG stably expressed in CHO cells at -80 mV by automated Qpatch electrophysiological assay
Inhibition of human ERG stably expressed in CHO cells at -80 mV by automated Qpatch electrophysiological assay
|
[PMID: 31910018] |
| HepG2 | IC50 |
>100 μM
Compound: 92125547
|
HARVARD: Cytotoxicity in HepG2 cell line
HARVARD: Cytotoxicity in HepG2 cell line
|
[PMID: 22586124] |
| HepG2 | IC50 |
1.05 μM
Compound: 92125547
|
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
|
[PMID: 22586124] |
| MRC5 | IC50 |
23.47 μM
Compound: CPX.Olamine
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
|
[PMID: 31910018] |
| SH-SY5Y | IC50 |
>100 μM
Compound: CPX.Olamine
|
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 31910018] |
In Vitro
Ciclopirox (10 μM, 18 h) olamine inhibits HUVEC proliferation and angiogenesis[4].
Ciclopirox (0-10 μM, 20 h) olamine inhibits deoxyhypusine hydroxylation in HUVECs[4].
Ciclopirox (0-40 μM, 72 h) olamine shows anti-tumor activity in H1299 and 95D cells (decreases cell viability, with IC50s of 11.13 and 4.136 μM respectively), and inhibits cell migration and invasion[5].
Ciclopirox (0-40 μM, 48 h) olamine arrests both H1299 and 95D cells in G1 phase, decreases Cyclin D1 and CDK4 protein level in H1299 and 95D cells[5].
Ciclopirox (0-20 μM) olamine induces cell aerobic glycolysis, impairs mitochondrial functions and enhances the generation of ROS in H1299 and 95D cells[5].
Ciclopirox (0-40 μM, 48 h) olamine activates PERK-dependent ER stress in CRC cells (HCT-8, HCT-8/5-FU, and DLD-1 cells)[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Ciclopirox (25 mg/kg, p.o., daily) olamine also inhibits tumor growth in human breast cancer MDA-MB231 xenografts in mice[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 41621-49-2
-
Appearance Solid
-
Peso molecular 268.35
-
Fòrmula C14H24N2O3
-
Color White to yellow
-
SMILES
O=C1C=C(C)C=C(C2CCCCC2)N1O.NCCO
-
Synonyms
Ciclopirox ethanolamine; HOE 296
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Dis
A novel taxane SB-T-101141 triggers a noncanonical ferroptosis to overcome Paclitaxel resistance of breast cancer via iron homeostasis-related KHSRP. [Abstract]2025 May 19;16(1):403. PMID: 40389408 -
Cell Death Dis
2024 Nov 1;15(11):786. PMID: 39487118
Ciclopirox olamine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Nov 1;15(11):786. [Abstract]
Western blotting analysis of OMA1 and mitophagy-related proteins in OS cells treated with CPX (Ciclopirox, 0-20 μM) for 24 h.
Ciclopirox olamine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Nov 1;15(11):786. [Abstract]
RT-qPCR analysis of OMA1 mRNA levels in OS cells treated with CPX (Ciclopirox, 0-20 μM) for 24 h.
Ciclopirox olamine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Nov 1;15(11):786. [Abstract]
Western blotting analysis of OMA1 protein in OS cells co-treated with CPX (20 µM) and a serial dose of MG132 for 24 h.
Ciclopirox olamine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Nov 1;15(11):786. [Abstract]
Endogenous ubiquitination levels of OMA1 in OS cells treated with CPX (20 µM) for 24 h were determined using an immunoprecipitation assay.
Ciclopirox olamine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Nov 1;15(11):786. [Abstract]
Representative MRI images of nude mice with right proximal tibia injected control or OMA1-deficient 143B cells for 4 weeks were intraperitoneally injected with 0.9% NaCl or CPX (20 mg/kg) for 2 weeks (n = 3).
Ciclopirox olamine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Nov 1;15(11):786. [Abstract]
Immunohistochemical analysis of Ki67 and Cleaved-caspase 3 in the OS xenograft intraperitoneally injected with 0.9% NaCl or CPX (20 mg/kg, 2 weeks, ip).
-
Pharmacol Res
Deoxyhypusine hydroxylase as a novel pharmacological target for ischemic stroke via inducing a unique post-translational hypusination modification. [Abstract]2022 Feb:176:106046. PMID: 35007708 -
Adv Healthc Mater
Iron Drives Eosinophil Differentiation in Allergic Airway Inflammation Through Mitochondrial Metabolic Adaptation. [Abstract]2025 Mar;14(7):e2405085. PMID: 39853900
Ciclopirox olamine purchased from MedChemExpress. Usage Cited in: Adv Healthc Mater. 2025 Mar;14(7):e2405085. [Abstract]
Intervention with CPX (Ciclopirox olamine, 1 μM) on day 4 during BMDE differentiation, followed by assessment of BMDE proportions and counts on day 9.
Ciclopirox olamine purchased from MedChemExpress. Usage Cited in: Adv Healthc Mater. 2025 Mar;14(7):e2405085. [Abstract]
Flow cytometry analysis of cell viability under CPX (Ciclopirox olamine) treatment using DAPI staining.
Ciclopirox olamine purchased from MedChemExpress. Usage Cited in: Adv Healthc Mater. 2025 Mar;14(7):e2405085. [Abstract]
Intervention with Fe2+ (10 μM) and DFO or CPX (Ciclopirox olamine) during BMDE differentiation, followed by examination of BMDE counts.
-
-
Clin Transl Med
Iron controls T helper cell pathogenicity by promoting glucose metabolism in autoimmune myopathy. [Abstract]2022 Aug;12(8):e999. PMID: 35917405 -
-
J Agric Food Chem
Zearalenone Regulates Energy Metabolism and Proliferation of Goat Endometrial Epithelial Cells through Estrogen Receptor 1. [Abstract]2025 Aug 13;73(32):20385-20395. PMID: 40762316 -
Eur J Pharmacol
Ciclopirox inhibits NLRP3 inflammasome activation via protecting mitochondria and ameliorates imiquimod-induced psoriatic inflammation in mice. [Abstract]2022 Sep 5:930:175156. PMID: 35868446 -
Mol Neurobiol
Stress-mediated Activation of Ferroptosis, Pyroptosis, and Apoptosis Following Mild Traumatic Brain Injury Exacerbates Neurological Dysfunctions. [Abstract]2025 Apr;62(4):4055-4075. PMID: 39388040 -
-
Front Pharmacol
Polyphyllin Ⅲ-Induced Ferroptosis in MDA-MB-231 Triple-Negative Breast Cancer Cells can Be Protected Against by KLF4-Mediated Upregulation of xCT. [Abstract]2021 May 10:12:670224. PMID: 34040532 -
ACS Chem Biol
2026 Jun 12. PMID: 42284103 -
Solvente y solubilidad
In Vitro:
DMSO : 25 mg/mL (93.16 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 20% SBE-β-CD in Saline
Solubility: 10 mg/mL (37.26 mM); Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Niewerth M, et al. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother. 2003 Jun;47(6):1805-17. [Content Brief]
[2]. Leem, S.H., et al., The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae. Mol Cells, 2003. 15(1): p. 55-61. [Content Brief]
[3]. Ratnavel, R.C., R.A. Squire, and G.C. Boorman, Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatolog Treat, 2007. 18(2): p. 88-96. [Content Brief]
[4]. Clement PM, et al. The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int J Cancer. 2002 Aug 1;100(4):491-8. [Content Brief]
[5]. Lu J, et al. Ciclopirox targets cellular bioenergetics and activates ER stress to induce apoptosis in non-small cell lung cancer cells. Cell Commun Signal. 2022 Mar 24;20(1):37. [Content Brief]
[6]. Zhou H, et al. The antitumor activity of the fungicide ciclopirox. Int J Cancer. 2010 Nov 15;127(10):2467-77. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7265 mL | 18.6324 mL | 37.2648 mL | 93.1619 mL |
| 5 mM | 0.7453 mL | 3.7265 mL | 7.4530 mL | 18.6324 mL | |
| 10 mM | 0.3726 mL | 1.8632 mL | 3.7265 mL | 9.3162 mL | |
| 15 mM | 0.2484 mL | 1.2422 mL | 2.4843 mL | 6.2108 mL | |
| 20 mM | 0.1863 mL | 0.9316 mL | 1.8632 mL | 4.6581 mL | |
| 25 mM | 0.1491 mL | 0.7453 mL | 1.4906 mL | 3.7265 mL | |
| 30 mM | 0.1242 mL | 0.6211 mL | 1.2422 mL | 3.1054 mL | |
| 40 mM | 0.0932 mL | 0.4658 mL | 0.9316 mL | 2.3290 mL | |
| 50 mM | 0.0745 mL | 0.3726 mL | 0.7453 mL | 1.8632 mL | |
| 60 mM | 0.0621 mL | 0.3105 mL | 0.6211 mL | 1.5527 mL | |
| 80 mM | 0.0466 mL | 0.2329 mL | 0.4658 mL | 1.1645 mL |
Ciclopirox olamine Related Classifications
HY-B0450A Related Classifications
Powered by Bioz